Aviva Capital Partners and Socius secure consent for £1bn London Cancer Hub expansion

The planning consent marks the pivotal milestone for a £1bn extension to the London Cancer Hub in Sutton. The new campus will add approximately one million sq ft of laboratory and research space, building on the existing hub infrastructure. Aviva Capital Partners is deploying Aviva's balance sheet capital into the scheme through its in-house regeneration and science platform. Aviva Capital Partners is Aviva's in-house capital unit focused on UK infrastructure and regeneration. Socius is a specialist development manager for science, technology, and mixed-use projects. The scheme aligns with the UK government's Life Sciences Sector Plan to stimulate scientific advancement over the next decade. £1bn total development value. Aviva Capital Partners is funding the scheme from Aviva's balance sheet capital. No debt financing details publicly disclosed for the initial phase.